

Статьи в высокорейтинговых журналах, индексируемых в WOS в 2018 г.

1. Anand S.S., Bosch J., Eikelboom J. W., Connolly S. J., Diaz R., Widimsky P., Aboyans V., Alings M., Kakkar A. K., Keltai K., Maggioni A. P., Lewis B. S., Stork S., Zhu J., Lopez-Jaramillo P., O'Donnell M., Commerford P. J., Vinereanu D., Pogossova N., Ryden L., Fox K. A., Bhatt D. L., Misselwitz F., Varigos J. D., Vanassche T., Avezum A. A., Chen E., Branch K., Leong D. P., Bangdiwala S. I., Hart R.G., Yusuf S., Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. // *The Lancet* 2018. 391, 10117, 219-229 Импакт фактор: WOS: 60.392 SJR: 14.554 DOI: **10.1016/ S0140-6736(17)32409-1**
2. Murphy A., Johnson C.O., Roth G.A., Forouzanfar M.H., Naghavi M., Ng M., Vos T., Murray C.J.L., Pogossova N., Moran A.E. , Ischaemic heart disease in the former Soviet Union 1990-2015 according to the Global Burden of Disease 2015 Study // *Heart* 2018. 104 , 1, 58-U214 Импакт фактор: WOS: 5.213 SJR: 2.229 DOI: **10.1136/ heartjnl-2016-311142**
3. Turchinovich A., Baranova A., Drapkina O., Tonevitsky A., Cell-Free circulating nucleic acids as early biomarkers for NAFLD and NAFLD-Associated disorders // *Frontiers in Physiology* 2018. 9, № статьи 1256, 1-13 Импакт фактор: WOS: 3.367 SJR: 1.211 DOI: **10/3389/fphys.2018.01256**
4. Kontsevaya A., Bobrova N., Bates K., Goryachkin E., Leon D.A., McKee M., Management of acute myocardial infarction in the Russian Federation: characteristics of patients and their treatment in hospitals // *European Journal of Heart Failure* 2018. 28, 4, 299-299 Импакт фактор: WOS: 11.627 SJR: 5.556 DOI: **10.1093/eurpub/cky213.877**
5. Nilsson PM., Laurent S., Cunha PG., Olsen MH., Rietzschel E., Franco OH., Ryliskyte L., Strazhesko I., Vlachopoulos C., Chen CH., Boutouyrie P., Cucca F., Lakatta EG., Scuteri A., Characteristics of healthy vascular ageing in pooled population-based cohort studies: the global Metabolic syndrome and Artery REsearch Consortium // *Journal of Hypertension* 2018. 36, 12, 2340-2349 Импакт фактор: WOS: 4.171 SJR: 1.365 DOI: **10.1097/HJH.0000000000001824**
6. Shang Ce, Yagav M., Stoklosa M., Kontsevaya A., Lewis F. B., Pana A., Reyes I., Country-specific costs of implementing the WHO FCTC tobacco control policies and potential financing sources // *PLoS ONE* 2018. 13, 10, e0204903 Импакт фактор: WOS: 2.74 SJR: 1.023 DOI: **10.1371/journal.pone.0204903**
7. Alexandra Ershova, Alexey Meshkov, and other authors, Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) //

Atherosclerosis 2018. 277, , 234-255 Импакт фактор: WOS: 3.919 SJR: 1.515
DOI: 10.1016/j.atherosclerosis.2018.08.051

8. Schwartz G.G., Steg P.G., Szarek M., Bhatt D.L., Bittner V.A., Diaz R., Edelberg J.M., Goodman S.G., Hanotin C., Harrington R.A., Jukema J.W., Lecorps G., Mahaffey K.W., Moryusef A., Pordy R., Quintero K., Roe M.T., Sasiela W.J., Tamby J.F., Tricoci P., White H.D., Zeiher A.M., Molchanova O.V., Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome // New England Journal of Medicine 2018. 379, 22, 2097-2107 Импакт фактор: WOS: 74.699 SJR: 18.291 **DOI: 10.1056/NEJMoa1801174**

9. Pogosova N., Oganov R., Saner H., Suvorov S., Sokolova O., Potential and limitations of health policy to improve coronary heart disease prevention and to reduce the burden of disease: A Russian experience. // European Journal of Preventive Cardiology 2018. 25, 16, 1725-1734 Импакт фактор: WOS: 5.864 SJR: 1.459 **DOI: 10.1177/2047487318768030**

10. Smedt D.D., Annemans L., Backer G.D., Kotseva K., Rydén L., Wood D., Amouyel P., Bruthans J., Cifkova R., Sutter J.D., Dolzhenko M., Erglis A., Gotcheva N., Gyberg V., Laucevicius A., Lovic D., Oganov R., Pajak A., Pogosova N., Reiner Ž., Stagmo M., Bacquer D.D. , Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey // International Journal of Cardiology 2018. 272, , 20-25 Импакт фактор: WOS: 3.229 SJR: 1.082 **DOI: 10.1016/j.ijcard.2018.06.104**

11. Poloznikov A., Gazarya I, Shkurnikov M, Nikulin S, Drapkina O., Baranova A, Tonevitsky A., In Vitro and In Silico Liver Models: Current Trends, Challenges and Opportunities // ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION 2018. 35, 3, 397-412 Импакт фактор: WOS: 5.787 SJR: 1.27 **DOI: 10.14573/altex.1803221**

12. Timonin S., Kontsevaya A., McKee M., Leon D. A., Reducing geographic inequalities in access times for acute treatment of myocardial infarction in a large country: the example of Russia // International Journal of Epidemiology 2018. 47, 5, 1594-1602 Импакт фактор: WOS: 7.707 SJR: 3.555 **DOI: 10.1093/ije/dyy146**

13. Barbitoff Y.A., Serebryakova E.A., Nasykhova Y.A., Predeus A.V., Polev D.E., Shuvalova A.R., Vasiliev E.V., Urazov S.P., Sarana A.M., Sherbak S.G., Gladyshev D.V., Pokrovskaya M.S., Sivakova O.V., Meshkov A.N., Drapkina O.M., Glotov O.S., Glotov A.S., Identification of novel candidate markers of type 2 diabetes and obesity in Russia by exome sequencing with a limited sample size // Genes 2018. 9, 415, 1-14 Импакт фактор: WOS: 3.759 SJR: 1.564 **DOI: 10/3390/genes9080415**

14. Glezer M., Vygodin V., Anti-Anginal Effectiveness and Tolerability of Trimetazidine Modified Release 80Mg Once Daily in Stable Angina Patients in Real-World Practice // *Advances in Therapy* 2018. 35, 9, 1368-1377 **Импакт фактор:** WOS: 3.871 SJR: 0.979 **DOI: 10.1007/s12325-018-0756-3**
15. Gerstein H. C., Colhoun H. M., Dagenais G. R., Diaz R., Lakshmanan M., Pais P., Probstfield J., Riddle M.C., Ryden L., Xavier D., Atisso C. M., Avezum A., Basile J., Chung N., Conget I., Cushman W. C., Franek E., Hancu N., Hanefeld M., Holt S., Jansky P., Keltai M., Lanas F., Leiter L. A., Lopez-Jaramillo P., German E., Munoz C., Pirags V., Pogosova N., Raubenheimer P. J., Shaw J., Sheu W., Temelkova-Kurktschiev T., Design and Baseline Characteristics of Participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) Trial on the cardiovascular effects of Dulaglutide // *Diabetes, Obesity and Metabolism* 2018. 20, 1, 42-49 **Импакт фактор:** WOS: 5.9 SJR: 2.497 **DOI: 10.1111/dom.13028**
16. Langhorne P., O'Donnell M.J., Chin S.L., Zhang H., Xavier D., Avezum A., Mathur N., Turner M., MacLeod M.J., Pogosova N., Ausheva A., Karpova A., Pshenichnikova V., Vertkin A., Kursakov A., Boytsov S., Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study // *The Lancet* 2018. 391, 10134, 2019-2027 **Импакт фактор:** WOS: 60.392 SJR: 14.554 **DOI: 10.1016/S0140-6736(18)30802-X**
17. Niccoli G., D'Amario D., Borovac J.A., Santangelo E., Scalone G., Fracassi F., Vergallo R., Vetrugno V., Copponi G., Severino A., Liuzzo G., Imaeva A., Siracusanò A., Crea F., Perilipin 2 levels are increased in patients with in-stent neoatherosclerosis: A clue to mechanisms of accelerated plaque formation after drug-eluting stent implantation // *International Journal of Cardiology* 2018. 258, 1, 55-58 **Импакт фактор:** WOS: 3.229 SJR: 1.082 **DOI: 10.1016/j.ijcard.2018.01.074**
18. Cheung D.G., Aizenberg D., Gorbunov V.M., Hafeez K., Chen C.W., Zhang J., Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study // *Journal of Clinical Hypertension* 2018. 20, 1, 150-158 **Импакт фактор:** WOS: 2.756 SJR: 0.916 **DOI: 10.1111/jch.13153**